Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

EXV-801

Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Timeline

Expected Milestones

Q1 2029

Phase 2/3Recruiting

Agitation

NCT07284472

Clinical

Trials by Indication[1]

Agitation1 trial

Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia

Recruiting·EExciva GmbH·Phase 2/3·NCT07284472·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for EXV-801. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — EXV-801 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for EXV-801. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Exciva GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: EExciva GmbH

Related News